|
Springworks Therapeutics, Inc. (SWTX) DCF Valoración
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
SpringWorks Therapeutics, Inc. (SWTX) Bundle
¡Explore el futuro financiero de Springworks Therapeutics, Inc. (SWTX) con nuestra calculadora DCF fácil de usar! Ingrese sus suposiciones con respecto al crecimiento, los márgenes y los costos para descubrir el valor intrínseco de Springworks Therapeutics, Inc. (SWTX) y mejorar su estrategia de inversión.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | 35.0 | .0 | 6.1 | 5.4 | 3.9 | 2.8 | 2.0 | 1.5 | 1.1 |
| Revenue Growth, % | 0 | 0 | -100 | 0 | -11.39 | -27.85 | -27.85 | -27.85 | -27.85 | -27.85 |
| EBITDA | -59.0 | -46.0 | -173.0 | -280.7 | -341.3 | -.8 | -.6 | -.4 | -.3 | -.2 |
| EBITDA, % | 100 | -131.36 | 100 | -4566.03 | -6266.68 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | .2 | .3 | .5 | 1.9 | 1.7 | 2.1 | 1.5 | 1.1 | .8 | .6 |
| Depreciation, % | 100 | 0.99714 | 100 | 30.84 | 30.6 | 52.49 | 52.49 | 52.49 | 52.49 | 52.49 |
| EBIT | -59.2 | -46.3 | -173.5 | -282.6 | -343.0 | -.8 | -.6 | -.4 | -.3 | -.2 |
| EBIT, % | 100 | -132.35 | 100 | -4596.88 | -6297.28 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 327.7 | 508.5 | 373.5 | 597.0 | 479.2 | 3.9 | 2.8 | 2.0 | 1.5 | 1.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | 5.9 | 2.4 | 1.7 | 1.2 | .9 | .6 |
| Account Receivables, % | 100 | 0 | 100 | 0 | 108.87 | 60 | 60 | 60 | 60 | 60 |
| Inventories | .0 | .0 | .0 | .0 | 3.1 | 2.0 | 1.5 | 1.1 | .8 | .5 |
| Inventories, % | 100 | 0 | 100 | 0 | 56.97 | 51.39 | 51.39 | 51.39 | 51.39 | 51.39 |
| Accounts Payable | 2.7 | 1.4 | 3.4 | 8.0 | 7.4 | 3.2 | 2.3 | 1.7 | 1.2 | .9 |
| Accounts Payable, % | 100 | 3.86 | 100 | 130.31 | 135.78 | 80.77 | 80.77 | 80.77 | 80.77 | 80.77 |
| Capital Expenditure | -.7 | -.6 | -2.0 | -10.2 | -7.4 | -1.6 | -1.1 | -.8 | -.6 | -.4 |
| Capital Expenditure, % | 100 | -1.83 | 100 | -165.87 | -135.58 | -40.37 | -40.37 | -40.37 | -40.37 | -40.37 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -55.6 | -45.0 | -172.8 | -279.3 | -343.0 | -.8 | -.6 | -.4 | -.3 | -.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -53.5 | -46.6 | -172.2 | -283.0 | -358.4 | .1 | .1 | .1 | .1 | .0 |
| WACC, % | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 |
| PV UFCF | ||||||||||
| SUM PV UFCF | .4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 1 | |||||||||
| Present Terminal Value | 1 | |||||||||
| Enterprise Value | 1 | |||||||||
| Net Debt | -169 | |||||||||
| Equity Value | 170 | |||||||||
| Diluted Shares Outstanding, MM | 63 | |||||||||
| Equity Value Per Share | 2.69 |
What You Will Get
- Real SpringWorks Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for SpringWorks Therapeutics, Inc. (SWTX).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to suit your analysis needs.
- Instant Valuation Updates: Automatic recalculations to assess the impact of changes on SpringWorks' fair value.
- Versatile Excel Template: Designed for quick edits, scenario testing, and comprehensive projections.
- Time-Saving and Accurate: Eliminate the hassle of building models from scratch while ensuring precision and adaptability.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for SpringWorks Therapeutics, Inc. (SWTX).
- WACC Calculator: Pre-built Weighted Average Cost of Capital sheet with customizable inputs specific to the biotech sector.
- Customizable Forecast Assumptions: Adjust growth rates, research and development expenditures, and discount rates as needed.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to SpringWorks Therapeutics, Inc. (SWTX).
- Interactive Dashboard and Charts: Visual representations that summarize key valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered SpringWorks Therapeutics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for SpringWorks Therapeutics' intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose SpringWorks Therapeutics, Inc. (SWTX)?
- Innovative Solutions: Access cutting-edge therapies designed to tackle unmet medical needs.
- Commitment to Quality: Rigorous research and development processes ensure high standards.
- Patient-Centric Approach: Focused on improving patient outcomes through tailored treatments.
- Expert Team: Collaborate with industry leaders and experienced professionals in the field.
- Proven Track Record: Backed by successful clinical trials and positive patient feedback.
Who Should Use This Product?
- Individual Investors: Gain insights to make informed decisions about buying or selling SpringWorks Therapeutics stock (SWTX).
- Financial Analysts: Enhance valuation processes with comprehensive financial models tailored for SpringWorks Therapeutics.
- Consultants: Provide clients with accurate and timely valuation insights for SpringWorks Therapeutics.
- Business Owners: Learn how biotech companies like SpringWorks Therapeutics are valued to inform your own business strategies.
- Finance Students: Explore valuation methodologies using real-world data and case studies from SpringWorks Therapeutics.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled SpringWorks Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for SpringWorks Therapeutics (SWTX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.